39062-63-0

Usage

Uses

Used in Perfumery Industry:
BENZOIC ACID, 2-CHLORO-5-HYDROXY-, ETHYL ESTER is used as a fragrance ingredient for its sweet and aromatic scent, enhancing the olfactory profile of various perfumes and colognes.
Used in Flavoring Industry:
In the flavoring industry, BENZOIC ACID, 2-CHLORO-5-HYDROXY-, ETHYL ESTER is used as a flavor enhancer to impart a pleasant and sweet taste to food products and beverages.
Used in Pharmaceutical Industry:
BENZOIC ACID, 2-CHLORO-5-HYDROXY-, ETHYL ESTER is utilized as an active pharmaceutical ingredient or as a component in the formulation of medications, capitalizing on its potential anti-inflammatory and antimicrobial properties to treat various conditions.
Used in Cosmetic Industry:
This ester is also used in the cosmetic industry as a component in skincare and beauty products, leveraging its aromatic qualities and potential therapeutic effects to improve product efficacy and user experience.

InChI:InChI=1/C9H9ClO3/c1-2-13-9(12)7-5-6(11)3-4-8(7)10/h3-5,11H,2H2,1H3

Upstream product

• 64-17-5 ethanol 
• 56961-30-9 2-chloro-5-hydroxybenzoic acid 

Downstream Products

• 39062-64-1 5-(benzyloxy)-2-chlorobenzoic acid 
• 1621680-91-8 4-(2-chloro-5-isobutoxybenzamido)-3,5-dimethylbenzoic acid 
• 1237079-75-2 2-chloro-5-isobutoxybenzoic acid 
• 1621681-31-9 4-(2-chloro-5-isobutoxy-N-methylbenzamido)-3,5-dimethylbenzoic acid 
• 1621681-46-6 ethyl 2-chloro-5-isobutoxybenzoate 
• 1552286-92-6 C₁₉H₁₈ClN₅O₂ 
• 1552286-91-5 C₁₉H₁₆ClN₅O₂ 
• 1552286-86-8 C₂₁H₂₀ClN₅O₂ 
• 1552286-63-1 C₁₉H₁₈ClN₅O₂ 
• 1552286-61-9 C₁₈H₁₆ClN₅O₂ 
• 1552286-60-8 C₁₈H₁₆ClN₅O₂ 

Relevant academic research and scientific papers

NOVEL PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATING THE CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS)

The present invention provides a compound of Formula (I) being capable of modulating the activity of histone lysine demethylase (KDM), pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The compound of Formula (I) acts as KDM inhibitor with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to KDM dysregulation.

4-METHYL-2,3,5,9,9B-PENTAAZA-CYCLOPENTA[A]NAPHTHALENES

The invention relates to 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalene derivatives of general formula (I) which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes

The invention relates to 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalene derivatives of general formula (I) which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

Substituted benzamides with activity towards EP4 receptors

The present invention belongs to the field of EP4 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP4 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP4 receptor as well as to pharmaceutical compositions comprising them.

SUBSTITUTED BENZAMIDES WITH ACTIVITY TOWARDS EP4 RECEPTORS

The present invention belongs to the field of EP4 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP4 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP4 receptor as well as to pharmaceutical compositions comprising them.